Treatment of resistance to pemigatinib

Pemigatinib (Pemigatinib) is a targeted therapy for locally advanced or metastatic cholangiocarcinoma (CCA) with FGFR2 gene mutations, The recommended dose is oral once daily< /span>13.5mg, Patients may develop drug resistance after receiving pemetinib treatment, which may be caused by insufficient original dose. You can consider gradually increasing the dose of pemetinib to achieve a more effective anti-tumor effect, but this needs to be done under the supervision of a doctor.

Pemetinib can also be used in combination with other drugs, such as chemotherapy drugs, immunotherapy or other targeted therapy drugs. Combination therapy can attack cancer cells through multiple pathways at the same time, improve the therapeutic effect and reduce the development of drug resistance. If pemetinib fails, tumor cells can be genetically sequenced and mutated to find new targets, and they can also participate in clinical trials targeting pemetinib resistance, which can help identify other targeted drugs or treatments that may be effective for patients.

The original drug of pemetinib has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. The price of each box of 4.5mg*14 tablets may be around 30,000 yuan, which is expensive. The price of the original pemetinib drug, 13.5mg*14 tablets, per box sold overseas may be around RMB 70,000 (the price may fluctuate due to exchange rates). There are also generic pemetinib drugs produced in other countries overseas. For example, the price of a box of 4.5mg*21 tablets produced by a Laos pharmaceutical factory may be around 3,000 yuan (the price may fluctuate due to the exchange rate). The price is relatively cheap. The pharmaceutical ingredients of the generic drugs are basically the same as those of the original drugs at home and abroad.